2.3.1.20 Adrenocortical Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34353633&form=6&db=m Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics. causal interaction,diagnostic usage,unassigned 3,4,0 2.3.1.20 Alopecia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15569818&form=6&db=m Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.3.1.20 Alopecia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19028692&form=6&db=m Retinol Esterification by DGAT1 Is Essential for Retinoid Homeostasis in Murine Skin. causal interaction,therapeutic application,unassigned 3,1,0 2.3.1.20 Alopecia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25112279&form=6&db=m Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.3.1.20 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23695883&form=6&db=m Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1?, and NF-?B activators' expression in pristane-induced arthritis. unassigned - 2.3.1.20 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17614133&form=6&db=m Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms. causal interaction,unassigned 1,0 2.3.1.20 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21045115&form=6&db=m Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. ongoing research,unassigned 1,0 2.3.1.20 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21924378&form=6&db=m Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 2.3.1.20 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32882484&form=6&db=m Intestine-specific DGAT1 deficiency improves atherosclerosis in apolipoprotein E knockout mice by reducing systemic cholesterol burden. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 2.3.1.20 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33235909&form=6&db=m DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 2.3.1.20 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15308631&form=6&db=m Overexpression of human diacylglycerol acyltransferase 1, acyl-coa:cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells. causal interaction,ongoing research,unassigned 1,4,0 2.3.1.20 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18937486&form=6&db=m Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25164810&form=6&db=m Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis. ongoing research,unassigned 2,0 2.3.1.20 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25244504&form=6&db=m Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2. causal interaction,ongoing research,unassigned 1,2,0 2.3.1.20 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31078041&form=6&db=m Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression. ongoing research,unassigned 4,0 2.3.1.20 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32561790&form=6&db=m The Role of Bone Morphogenetic Protein Signaling in Non-Alcoholic Fatty Liver Disease. causal interaction,therapeutic application,unassigned 1,1,0 2.3.1.20 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32749667&form=6&db=m CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4? and DGAT2 expression. therapeutic application,unassigned 3,0 2.3.1.20 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33794741&form=6&db=m The ménage à trois of autophagy, lipid droplets and liver disease. ongoing research,unassigned 2,0 2.3.1.20 Cardiomegaly http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22918576&form=6&db=m Reduction of Rat Cardiac Hypertrophy by Osthol is Related to Regulation of Cardiac Oxidative Stress and Lipid Metabolism. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21220706&form=6&db=m A murine model of isolated cardiac steatosis leads to cardiomyopathy. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 2.3.1.20 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22628613&form=6&db=m Diacylglycerol acyl transferase 1 overexpression detoxifies cardiac lipids in PPAR? transgenic mice. therapeutic application,unassigned 1,0 2.3.1.20 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25300978&form=6&db=m Inborn errors of cytoplasmic triglyceride metabolism. unassigned - 2.3.1.20 ceramidase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32474112&form=6&db=m Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 2.3.1.20 Charcot-Marie-Tooth Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26786738&form=6&db=m DGAT2 Mutation in a Family with Autosomal Dominant Early-Onset Axonal Charcot-Marie-Tooth Disease. unassigned - 2.3.1.20 Citrullinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 coagulation factor xia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33326472&form=6&db=m Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators. diagnostic usage,ongoing research,unassigned 3,4,0 2.3.1.20 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12814629&form=6&db=m Stability of diacylglycerol acyltransferase in dehydrated bovine muscle tissue. diagnostic usage,therapeutic application,unassigned 3,3,0 2.3.1.20 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23928127&form=6&db=m The important role of epidermal triacylglycerol metabolism for maintenance of the skin permeability barrier function. causal interaction,unassigned 2,0 2.3.1.20 Dermatitis, Phototoxic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27471837&form=6&db=m The DGAT1 inhibitor pradigastat does not induce photosensitivity in healthy human subjects: a randomized controlled trial using three defined sunlight exposure conditions. ongoing research,therapeutic application,unassigned 1,2,0 2.3.1.20 Dermatitis, Phototoxic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31413796&form=6&db=m Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor. therapeutic application,unassigned 4,0 2.3.1.20 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14683457&form=6&db=m DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17510710&form=6&db=m Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 2.3.1.20 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18937486&form=6&db=m Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23539897&form=6&db=m RNA interference-mediated knockdown of DGAT1 decreases triglyceride content of bovine mammary epithelial cell line. causal interaction,ongoing research,unassigned 4,2,0 2.3.1.20 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24118885&form=6&db=m Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14683457&form=6&db=m DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15569818&form=6&db=m Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16448557&form=6&db=m Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17177498&form=6&db=m Inhibition of diacylglycerol acyltransferase by alkamides isolated from the fruits of Piper longum and Piper nigrum. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17510710&form=6&db=m Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19183875&form=6&db=m Diacylglycerol acyltransferase-inhibitory compounds from Erythrina senegalensis. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20195824&form=6&db=m Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21254273&form=6&db=m Isolation of Diacyl Glycerol Acyl Transferase (DGAT) Inhibitors from Pachydictyon coriaceum. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21990351&form=6&db=m Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22950654&form=6&db=m Proof of mechanism for the DGAT1 inhibitor AZD7687: Results from a first-time-in-human single dose study. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23871442&form=6&db=m Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24118885&form=6&db=m Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26493024&form=6&db=m Prolonged silencing of diacylglycerol acyltransferase-1 induces a dedifferentiated phenotype in human liver cells. causal interaction,unassigned 4,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26806569&form=6&db=m Effects of Morus root bark extract and active constituents on blood lipids in hyperlipidemia rats. causal interaction,therapeutic application,unassigned 1,2,0 2.3.1.20 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33347980&form=6&db=m A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10802663&form=6&db=m Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11805129&form=6&db=m Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands. causal interaction,ongoing research,unassigned 2,2,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11956242&form=6&db=m Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12123490&form=6&db=m DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women. causal interaction,unassigned 4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12130553&form=6&db=m Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12782674&form=6&db=m Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15161747&form=6&db=m Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15569818&form=6&db=m Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16448557&form=6&db=m Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16595853&form=6&db=m Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17510710&form=6&db=m Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19028692&form=6&db=m Retinol Esterification by DGAT1 Is Essential for Retinoid Homeostasis in Murine Skin. causal interaction,therapeutic application,unassigned 3,1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19472314&form=6&db=m Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. ongoing research,therapeutic application,unassigned 3,4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19690167&form=6&db=m Sterol and diacylglycerol acyltransferase deficiency triggers fatty acid mediated cell death. causal interaction,ongoing research,unassigned 2,2,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21205704&form=6&db=m DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. causal interaction,unassigned 1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21924378&form=6&db=m Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22911105&form=6&db=m Intestinal DGAT1 deficiency markedly reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. causal interaction,unassigned 2,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23336002&form=6&db=m Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24272998&form=6&db=m Palmitic Acid and DGAT1 Deficiency Enhance Osteoclastogenesis while Oleic Acid-Induced Triglyceride Formation Prevents it. causal interaction,unassigned 4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26883093&form=6&db=m Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27223895&form=6&db=m Acyl-CoA:Diacylglycerol Acyltransferase 1 Expression Level in the Hematopoietic Compartment Impacts Inflammation in the Vascular Plaques of Atherosclerotic Mice. therapeutic application,unassigned 1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27344248&form=6&db=m Novel role of a triglyceride-synthesizing enzyme: DGAT1 at the crossroad between triglyceride and cholesterol metabolism. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29604290&form=6&db=m Intestinal failure and aberrant lipid metabolism in patients with DGAT1 deficiency. causal interaction,ongoing research,unassigned 4,2,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30342099&form=6&db=m DGAT1 deficiency disrupts lysosome function in enterocytes during dietary fat absorption. causal interaction,unassigned 1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31081165&form=6&db=m Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31657789&form=6&db=m A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32882484&form=6&db=m Intestine-specific DGAT1 deficiency improves atherosclerosis in apolipoprotein E knockout mice by reducing systemic cholesterol burden. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 2.3.1.20 diacylglycerol o-acyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33261563&form=6&db=m DGAT1 mutations leading to delayed chronic diarrhoea: a case report. causal interaction,unassigned 4,0 2.3.1.20 Dwarfism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18834848&form=6&db=m A simple homogeneous scintillation proximity assay for acyl-coenzyme A:diacylglycerol acyltransferase. causal interaction,therapeutic application,unassigned 1,1,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21220706&form=6&db=m A murine model of isolated cardiac steatosis leads to cardiomyopathy. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21413799&form=6&db=m Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22315393&form=6&db=m Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24120540&form=6&db=m Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy. therapeutic application,unassigned 4,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25997070&form=6&db=m Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27245430&form=6&db=m Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis. causal interaction,unassigned 4,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29706567&form=6&db=m DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates. causal interaction,therapeutic application,unassigned 2,4,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30251338&form=6&db=m Elevated metabolic rate and skeletal muscle oxidative metabolism contribute to the reduced susceptibility of NF-?B p50 null mice to obesity. causal interaction,unassigned 4,0 2.3.1.20 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33347980&form=6&db=m A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Dystocia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29892901&form=6&db=m Deciphering signature of selection affecting beef quality traits in Angus cattle. diagnostic usage,therapeutic application,unassigned 1,1,0 2.3.1.20 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30718413&form=6&db=m DGAT1 inhibits retinol-dependent regulatory T cell formation and mediates autoimmune encephalomyelitis. ongoing research,unassigned 2,0 2.3.1.20 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30718413&form=6&db=m DGAT1 inhibits retinol-dependent regulatory T cell formation and mediates autoimmune encephalomyelitis. ongoing research,unassigned 2,0 2.3.1.20 Escherichia coli Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30563203&form=6&db=m Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis. causal interaction,ongoing research,unassigned 4,3,0 2.3.1.20 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 Farber Lipogranulomatosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32474112&form=6&db=m Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3209508&form=6&db=m Hepatic triacylglycerol synthesis during a period of fatty liver development in sheep. unassigned - 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6491527&form=6&db=m Hepatic triacylglycerol synthesizing activity during progression of alcoholic liver injury in the baboon. causal interaction,unassigned 1,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17611927&form=6&db=m Osthole improves fat milk-induced fatty liver in rats: modulation of hepatic PPAR-alpha/gamma-mediated lipogenic gene expression. ongoing research,unassigned 2,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18696335&form=6&db=m Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARalpha/gamma in fat milk-induced fatty liver rats. diagnostic usage,ongoing research,unassigned 1,4,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18980578&form=6&db=m The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. causal interaction,ongoing research,unassigned 4,3,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19472314&form=6&db=m Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. ongoing research,therapeutic application,unassigned 3,4,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20478303&form=6&db=m Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets. causal interaction,ongoing research,unassigned 4,2,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20739640&form=6&db=m Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease. causal interaction,unassigned 3,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22355095&form=6&db=m Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing. therapeutic application,unassigned 4,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23086552&form=6&db=m Dietary fat composition influences tissue lipid profile and gene expression in Fischer-344 rats. therapeutic application,unassigned 1,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25083925&form=6&db=m Recent advances in pharmacotherapy for hypertriglyceridemia. causal interaction,therapeutic application,unassigned 3,3,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25123789&form=6&db=m Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A:diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25925967&form=6&db=m [6]-gingerol dampens hepatic steatosis and inflammation in experimental nonalcoholic steatohepatitis. unassigned - 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26031670&form=6&db=m Treatment of rats with Jiangzhi Capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2. therapeutic application,unassigned 1,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26215699&form=6&db=m JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis. therapeutic application,unassigned 1,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27245430&form=6&db=m Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis. causal interaction,unassigned 4,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28849079&form=6&db=m Betaine attenuates chronic alcohol?induced fatty liver by broadly regulating hepatic lipid metabolism. unassigned - 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30415861&form=6&db=m Perilipin 5 promotes hepatic steatosis in dairy cows through increasing lipid synthesis and decreasing very low density lipoprotein assembly. ongoing research,unassigned 1,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30773673&form=6&db=m Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31178189&form=6&db=m Low abundance of mitofusin 2 in dairy cows with moderate fatty liver is associated with alterations in hepatic lipid metabolism. ongoing research,unassigned 1,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32553151&form=6&db=m Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33794741&form=6&db=m The ménage à trois of autophagy, lipid droplets and liver disease. ongoing research,unassigned 2,0 2.3.1.20 Fatty Liver, Alcoholic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20739640&form=6&db=m Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease. causal interaction,unassigned 3,0 2.3.1.20 Genetic Diseases, Inborn http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29892901&form=6&db=m Deciphering signature of selection affecting beef quality traits in Angus cattle. diagnostic usage,therapeutic application,unassigned 1,1,0 2.3.1.20 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32559414&form=6&db=m Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress. ongoing research,unassigned 1,0 2.3.1.20 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33235909&form=6&db=m DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 2.3.1.20 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12782674&form=6&db=m Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 2.3.1.20 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16448557&form=6&db=m Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16595853&form=6&db=m Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16894240&form=6&db=m The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. diagnostic usage,ongoing research,unassigned 1,4,0 2.3.1.20 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30936184&form=6&db=m The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes. ongoing research,unassigned 2,0 2.3.1.20 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33450094&form=6&db=m Exposure to high fructose corn syrup during adolescence in the mouse alters hepatic metabolism and the microbiome in a sex-specific manner. ongoing research,unassigned 3,0 2.3.1.20 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25157099&form=6&db=m Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure. causal interaction,ongoing research,unassigned 3,1,0 2.3.1.20 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20196803&form=6&db=m Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. causal interaction,ongoing research,unassigned 1,3,0 2.3.1.20 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20935628&form=6&db=m Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,1 2.3.1.20 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21354164&form=6&db=m Diacylglycerol acyltransferase-1: a critical host factor for hepatitis C virus assembly and potential new drug target. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23420847&form=6&db=m Diacylglycerol glycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.3.1.20 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23919406&form=6&db=m Current Status of the Research and Development of Diacylglycerol O-Acyltransferase 1 (DGAT1) Inhibitors. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 2.3.1.20 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24899196&form=6&db=m Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells. unassigned - 2.3.1.20 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30127285&form=6&db=m Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor. causal interaction,unassigned 1,0 2.3.1.20 Hepatoblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12204791&form=6&db=m Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. diagnostic usage,ongoing research,unassigned 3,4,0 2.3.1.20 Hernia, Umbilical http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27344248&form=6&db=m Novel role of a triglyceride-synthesizing enzyme: DGAT1 at the crossroad between triglyceride and cholesterol metabolism. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21220706&form=6&db=m A murine model of isolated cardiac steatosis leads to cardiomyopathy. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 2.3.1.20 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6491527&form=6&db=m Hepatic triacylglycerol synthesizing activity during progression of alcoholic liver injury in the baboon. causal interaction,unassigned 1,0 2.3.1.20 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16001399&form=6&db=m Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 2.3.1.20 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20385122&form=6&db=m In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21052084&form=6&db=m Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.20 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23345190&form=6&db=m Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. therapeutic application,unassigned 4,0 2.3.1.20 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30422629&form=6&db=m Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). causal interaction,therapeutic application,unassigned 3,3,0 2.3.1.20 Hyperlipoproteinemia Type I http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25627776&form=6&db=m Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor. causal interaction,therapeutic application,unassigned 2,4,0 2.3.1.20 Hyperlipoproteinemia Type I http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25633714&form=6&db=m Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor. therapeutic application,unassigned 2,0 2.3.1.20 Hyperlipoproteinemia Type I http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25889044&form=6&db=m Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. causal interaction,ongoing research,unassigned 3,2,0 2.3.1.20 Hyperlipoproteinemia Type I http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25963481&form=6&db=m Evaluation of food effect on the oral bioavailability of pradigastat, a diacylglycerol acyltransferase 1 inhibitor. therapeutic application,unassigned 4,0 2.3.1.20 Hyperlipoproteinemia Type I http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27274009&form=6&db=m Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans. causal interaction,unassigned 2,0 2.3.1.20 Hyperlipoproteinemia Type I http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27855567&form=6&db=m Pradigastat disposition in humans: in vivo and in vitro investigations. therapeutic application,unassigned 1,0 2.3.1.20 Hyperlipoproteinemia Type I http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30403015&form=6&db=m Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. causal interaction,therapeutic application,unassigned 1,3,0 2.3.1.20 Hyperlipoproteinemia Type I http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31413796&form=6&db=m Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor. therapeutic application,unassigned 4,0 2.3.1.20 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15200432&form=6&db=m Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18252207&form=6&db=m Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19478132&form=6&db=m Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21538210&form=6&db=m Identification of diacylglycerol acyltransferase inhibitors from Rosa centifolia petals. causal interaction,unassigned 3,0 2.3.1.20 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25300978&form=6&db=m Inborn errors of cytoplasmic triglyceride metabolism. unassigned - 2.3.1.20 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26246845&form=6&db=m Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 2.3.1.20 Hypothyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3355527&form=6&db=m Comparison of triacylglycerol synthesis in rat brown and white adipocytes. Effects of hypothyroidism and streptozotocin-diabetes on enzyme activities and metabolic fluxes. unassigned - 2.3.1.20 Ichthyosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25300978&form=6&db=m Inborn errors of cytoplasmic triglyceride metabolism. unassigned - 2.3.1.20 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12502715&form=6&db=m A novel bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltransferase mediates wax ester and triacylglycerol biosynthesis in Acinetobacter calcoaceticus ADP1. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20935628&form=6&db=m Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,1 2.3.1.20 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23420847&form=6&db=m Diacylglycerol glycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.3.1.20 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30018616&form=6&db=m Necrosis Driven Triglyceride Synthesis Primes Macrophages for Inflammation During Mycobacterium tuberculosis Infection. unassigned - 2.3.1.20 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30563203&form=6&db=m Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis. causal interaction,ongoing research,unassigned 4,3,0 2.3.1.20 Infertility http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32106336&form=6&db=m On the Role of DGAT1 in Seed Glycerolipid Metabolic Network and Critical Stages of Plant Development in Arabidopsis. causal interaction,therapeutic application,unassigned 2,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11956242&form=6&db=m Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12130553&form=6&db=m Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12401709&form=6&db=m Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue. causal interaction,ongoing research,unassigned 4,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12782674&form=6&db=m Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14521909&form=6&db=m A novel diacylglycerol acyltransferase (DGAT2) is decreased in human psoriatic skin and increased in diabetic mice. unassigned - 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15161747&form=6&db=m Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15224651&form=6&db=m The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism. causal interaction,diagnostic usage,unassigned 1,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15550388&form=6&db=m Expression of DGAT2 in white adipose tissue is regulated by central leptin action. causal interaction,unassigned 4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16001399&form=6&db=m Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16306352&form=6&db=m Whole-body Insulin Resistance in the Absence of Obesity in FVB Mice With Overexpression of Dgat1 in Adipose Tissue. causal interaction,ongoing research,unassigned 3,3,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16448557&form=6&db=m Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16595853&form=6&db=m Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16894240&form=6&db=m The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. diagnostic usage,ongoing research,unassigned 1,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17239230&form=6&db=m Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17510710&form=6&db=m Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17526931&form=6&db=m Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17618857&form=6&db=m Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. ongoing research,unassigned 4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17940217&form=6&db=m Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle. ongoing research,unassigned 1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18460922&form=6&db=m Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. causal interaction,therapeutic application,unassigned 4,2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18980578&form=6&db=m The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. causal interaction,ongoing research,unassigned 4,3,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18986321&form=6&db=m Storing up trouble: does accumulation of intramyocellular triglyceride protect skeletal muscle from insulin resistance? causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19116371&form=6&db=m Beyond Triglyceride Synthesis: The Dynamic Functional Roles of MGAT and DGAT Enzymes in Energy Metabolism. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19675136&form=6&db=m Paradoxical coupling of triglyceride synthesis and fatty acid oxidation in skeletal muscle overexpressing DGAT1. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20124729&form=6&db=m DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. unassigned - 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20385122&form=6&db=m In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20820848&form=6&db=m Palmitate-induced skeletal muscle insulin resistance does not require NF-kappaB activation. therapeutic application,unassigned 1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21264296&form=6&db=m Paradoxical increase in TAG and DAG content parallel the insulin sensitizing effect of unilateral DGAT1 overexpression in rat skeletal muscle. ongoing research,unassigned 4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21413799&form=6&db=m Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21436037&form=6&db=m Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21990351&form=6&db=m Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22073239&form=6&db=m Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22268446&form=6&db=m Liver fat accumulation may be dissociated from adiposity gain in ovariectomized rats. causal interaction,therapeutic application,unassigned 3,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22385114&form=6&db=m Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23489367&form=6&db=m Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia. causal interaction,unassigned 3,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23512750&form=6&db=m Reduced skeletal muscle oxidative capacity and elevatedceramidebut not diacylglycerol content in severe obesity. causal interaction,diagnostic usage,unassigned 3,2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23585481&form=6&db=m Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24595352&form=6&db=m Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice. unassigned - 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24900321&form=6&db=m Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25099343&form=6&db=m Discovery of a novel class of diacylglycerol acyltransferase 2 inhibitors with a 1H-pyrrolo[2,3-b]pyridine core. causal interaction,therapeutic application,unassigned 2,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25405858&form=6&db=m Intestine-targeted DGAT1 inhibition improves obesity and insulin resistance without skin aberrations in mice. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26762066&form=6&db=m [Effect of Jinlida on DGAT1 in Skeletal Muscle in Fat-Induced Insulin Resistance ApoE -/- Mice]. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27245430&form=6&db=m Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis. causal interaction,unassigned 4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28386555&form=6&db=m Analysis of Differentially Expressed Genes in Gastrocnemius Muscle between DGAT1 Transgenic Mice and Wild-Type Mice. ongoing research,unassigned 2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29075849&form=6&db=m Decreased lipogenesis-promoting factors in adipose tissue in postmenopausal women with overweight on a Paleolithic-type diet. unassigned - 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30773673&form=6&db=m Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31019978&form=6&db=m Tangduqing Granules Attenuate Insulin Resistance and Abnormal Lipid Metabolism through the Coordinated Regulation of PPAR? and DGAT2 in Type 2 Diabetic Rats. causal interaction,therapeutic application,unassigned 3,2,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32650006&form=6&db=m Bromodomain-containing protein 4 regulates a cascade of lipid-accumulation-related genes at the transcriptional level in the 3T3-L1 white adipocyte-like cell line. ongoing research,unassigned 1,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32916011&form=6&db=m Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.20 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34361563&form=6&db=m Bioactive Compounds from Lemon (Citrus limon) Extract Overcome TNF-?-Induced Insulin Resistance in Cultured Adipocytes. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Intestinal Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29604290&form=6&db=m Intestinal failure and aberrant lipid metabolism in patients with DGAT1 deficiency. causal interaction,ongoing research,unassigned 4,2,0 2.3.1.20 Lipid Metabolism Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31019978&form=6&db=m Tangduqing Granules Attenuate Insulin Resistance and Abnormal Lipid Metabolism through the Coordinated Regulation of PPAR? and DGAT2 in Type 2 Diabetic Rats. causal interaction,therapeutic application,unassigned 3,2,0 2.3.1.20 Lipodystrophy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19472314&form=6&db=m Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. ongoing research,therapeutic application,unassigned 3,4,0 2.3.1.20 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18000880&form=6&db=m Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18301087&form=6&db=m Nonalcoholic fatty liver disease: emerging mechanisms and consequences. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18460922&form=6&db=m Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. causal interaction,therapeutic application,unassigned 4,2,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20739640&form=6&db=m Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease. causal interaction,unassigned 3,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24954424&form=6&db=m Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25083925&form=6&db=m Recent advances in pharmacotherapy for hypertriglyceridemia. causal interaction,therapeutic application,unassigned 3,3,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30580553&form=6&db=m n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review. ongoing research,unassigned 1,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30773673&form=6&db=m Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32553151&form=6&db=m Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33190588&form=6&db=m TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. ongoing research,unassigned 1,0 2.3.1.20 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33794741&form=6&db=m The ménage à trois of autophagy, lipid droplets and liver disease. ongoing research,unassigned 2,0 2.3.1.20 Liver Diseases, Alcoholic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30580553&form=6&db=m n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review. ongoing research,unassigned 1,0 2.3.1.20 Malnutrition http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31778854&form=6&db=m Genetic variants in DGAT1 cause diverse clinical presentations of malnutrition through a specific molecular mechanism. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,2,0 2.3.1.20 Maple Syrup Urine Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31779717&form=6&db=m Significant genetic effects of JAK2 and DGAT1 mutations on milk fat content and mastitis resistance in Holsteins. unassigned - 2.3.1.20 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32264818&form=6&db=m Distinguishing pleiotropy from linked QTL between milk production traits and mastitis resistance in Nordic Holstein cattle. ongoing research,unassigned 4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18183944&form=6&db=m Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. therapeutic application,unassigned 4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20021283&form=6&db=m Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21990351&form=6&db=m Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23336002&form=6&db=m Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23427273&form=6&db=m ACAT-selective and Nonselective DGAT1 Inhibition: Adrenocortical Effects--A Cross-species Comparison. therapeutic application,unassigned 3,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23585481&form=6&db=m Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24900877&form=6&db=m Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24954424&form=6&db=m Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25112279&form=6&db=m Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26189431&form=6&db=m Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid. unassigned - 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29986142&form=6&db=m Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH). causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30108796&form=6&db=m Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32737468&form=6&db=m DGAT1 inhibitors protect pancreatic ?-cells from palmitic acid-induced apoptosis. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32878484&form=6&db=m Patent landscape for discovery of promising acyltransferase DGAT and MGAT inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Metabolic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33347980&form=6&db=m A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16001399&form=6&db=m Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 2.3.1.20 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18937486&form=6&db=m Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19256504&form=6&db=m Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20047575&form=6&db=m SIRT6 protects against pathological damage caused by diet-induced obesity. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460795&form=6&db=m Novel acyl coenzyme A: diacylglycerol acyltransferase 1 inhibitors-synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21413799&form=6&db=m Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Muscular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25300978&form=6&db=m Inborn errors of cytoplasmic triglyceride metabolism. unassigned - 2.3.1.20 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32506038&form=6&db=m Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16956609&form=6&db=m Activation of diacylglycerol O-acyltransferase 1 gene results in increased tumor necrosis factor-alpha gene expression in 3T3-L1 adipocytes. causal interaction,unassigned 3,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23038002&form=6&db=m Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. unassigned - 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24767307&form=6&db=m Maternal supplementation with n-3 long chain polyunsaturated fatty acids during perinatal period alleviates the metabolic syndrome disturbances in adult hamster pups fed a high-fat diet after weaning. diagnostic usage,unassigned 1,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25062566&form=6&db=m Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1,25-dihydroxyvitamin D3 in diabetic rats. unassigned - 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25598079&form=6&db=m Cell-based assay of MGAT2-driven diacylglycerol synthesis for profiling inhibitors: use of a stable isotope-labeled substrate and high-resolution LC/MS. ongoing research,therapeutic application,unassigned 4,4,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25787885&form=6&db=m Direct and maternal n-3 long-chain polyunsaturated fatty acid supplementation improved triglyceridemia and glycemia through the regulation of hepatic and muscle sphingolipid synthesis in offspring hamsters fed a high-fat diet. ongoing research,unassigned 2,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26513060&form=6&db=m Intracellular mechanisms underlying lipid accumulation (white opaque substance) in gastric epithelial neoplasms: A pilot study of expression profiles of lipid-metabolism-associated genes. causal interaction,unassigned 1,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26576534&form=6&db=m Mining for novel candidate clock genes in the circadian regulatory network. ongoing research,unassigned 2,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27113481&form=6&db=m Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene. causal interaction,therapeutic application,unassigned 2,1,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27446205&form=6&db=m HDAC Inhibition Modulates Cardiac PPARs and Fatty Acid Metabolism in Diabetic Cardiomyopathy. unassigned - 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30580553&form=6&db=m n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review. ongoing research,unassigned 1,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30622377&form=6&db=m Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease. ongoing research,unassigned 3,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30816200&form=6&db=m DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31078041&form=6&db=m Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression. ongoing research,unassigned 4,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32506038&form=6&db=m Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32559414&form=6&db=m Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress. ongoing research,unassigned 1,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33190588&form=6&db=m TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. ongoing research,unassigned 1,0 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33235909&form=6&db=m DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33750350&form=6&db=m Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33824421&form=6&db=m Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34095320&form=6&db=m DGAT1 Expression Promotes Ovarian Cancer Progression and Is Associated with Poor Prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 2.3.1.20 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34439946&form=6&db=m Comprehensive Genetic Analysis of DGAT2 Mutations and Gene Expression Patterns in Human Cancers. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 2.3.1.20 Nephritis, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15200432&form=6&db=m Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30836997&form=6&db=m Inflammatory, regulatory, and autophagy co-expression modules and hub genes underlie the peripheral immune response to human intracerebral hemorrhage. therapeutic application,unassigned 1,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17526931&form=6&db=m Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17671740&form=6&db=m Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. causal interaction,unassigned 1,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18301087&form=6&db=m Nonalcoholic fatty liver disease: emerging mechanisms and consequences. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18460922&form=6&db=m Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. causal interaction,therapeutic application,unassigned 4,2,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25083925&form=6&db=m Recent advances in pharmacotherapy for hypertriglyceridemia. causal interaction,therapeutic application,unassigned 3,3,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26693162&form=6&db=m The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29986142&form=6&db=m Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH). causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30580553&form=6&db=m n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review. ongoing research,unassigned 1,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30773673&form=6&db=m Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31081165&form=6&db=m Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31776293&form=6&db=m Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. therapeutic application,unassigned 4,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32404278&form=6&db=m Niacin increases diet-induced hepatic steatosis in B6129 mice. therapeutic application,unassigned 1,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32553151&form=6&db=m Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32916011&form=6&db=m Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33190588&form=6&db=m TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. ongoing research,unassigned 1,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33794741&form=6&db=m The ménage à trois of autophagy, lipid droplets and liver disease. ongoing research,unassigned 2,0 2.3.1.20 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34351342&form=6&db=m CD36 and DGAT2 facilitate the lipid-lowering effect of chitooligosaccharides via fatty acid intake and triglyceride synthesis signaling. causal interaction,therapeutic application,unassigned 2,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10802663&form=6&db=m Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11282293&form=6&db=m DGAT and triglyceride synthesis: a new target for obesity treatment? causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11956242&form=6&db=m Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12062850&form=6&db=m Pathogenesis of obesity by food restriction in OLETF rats-increased intestinal monoacylglycerol acyltransferase activities may be a crucial factor. ongoing research,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12130553&form=6&db=m Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12388146&form=6&db=m Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT1. causal interaction,unassigned 3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12401709&form=6&db=m Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue. causal interaction,ongoing research,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12407108&form=6&db=m Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12782674&form=6&db=m Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14683457&form=6&db=m DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15550388&form=6&db=m Expression of DGAT2 in white adipose tissue is regulated by central leptin action. causal interaction,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15569818&form=6&db=m Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15797871&form=6&db=m Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. causal interaction,unassigned 3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16306352&form=6&db=m Whole-body Insulin Resistance in the Absence of Obesity in FVB Mice With Overexpression of Dgat1 in Adipose Tissue. causal interaction,ongoing research,unassigned 3,3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16448557&form=6&db=m Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16595853&form=6&db=m Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16894240&form=6&db=m The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. diagnostic usage,ongoing research,unassigned 1,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17177498&form=6&db=m Inhibition of diacylglycerol acyltransferase by alkamides isolated from the fruits of Piper longum and Piper nigrum. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17239230&form=6&db=m Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17477860&form=6&db=m Mutation screen and association studies in the diacylglycerol O-acyltransferase homolog 2 gene (DGAT2), a positional candidate gene for early onset obesity on chromosome 11q13. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17614133&form=6&db=m Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms. causal interaction,unassigned 1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17726433&form=6&db=m Hypertrophy and hyperplasia of abdominal adipose tissues in women. ongoing research,unassigned 1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17907060&form=6&db=m DGAT inhibitors for obesity. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18183944&form=6&db=m Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. therapeutic application,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18252207&form=6&db=m Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18571500&form=6&db=m An N-terminal fragment of mouse DGAT1 binds different acyl-CoAs with varying affinity. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18834848&form=6&db=m A simple homogeneous scintillation proximity assay for acyl-coenzyme A:diacylglycerol acyltransferase. causal interaction,therapeutic application,unassigned 1,1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18937486&form=6&db=m Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19116371&form=6&db=m Beyond Triglyceride Synthesis: The Dynamic Functional Roles of MGAT and DGAT Enzymes in Energy Metabolism. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19183875&form=6&db=m Diacylglycerol acyltransferase-inhibitory compounds from Erythrina senegalensis. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19256504&form=6&db=m Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20147738&form=6&db=m Intestine specific expression of acyl CoA:diacylgylcerol acyltransferase 1 (DGAT1) reverses resistance to diet-induced hepatic steatosis and obesity in Dgat1-/- mice. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20195824&form=6&db=m Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460795&form=6&db=m Novel acyl coenzyme A: diacylglycerol acyltransferase 1 inhibitors-synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20478303&form=6&db=m Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets. causal interaction,ongoing research,unassigned 4,2,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20509774&form=6&db=m Triazolo compounds useful as diacylglycerol acyltransferase1 inhibitor - WO2009126624. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20597032&form=6&db=m DGAT1 inhibitors as anti-obesity and anti-diabetic agents. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21034741&form=6&db=m A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21254273&form=6&db=m Isolation of Diacyl Glycerol Acyl Transferase (DGAT) Inhibitors from Pachydictyon coriaceum. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21413799&form=6&db=m Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21868220&form=6&db=m Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors. causal interaction,therapeutic application,unassigned 2,1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21933415&form=6&db=m Evolutionary view of acyl-CoA diacylglycerol acyltransferase (DGAT), a key enzyme in neutral lipid biosynthesis. causal interaction,therapeutic application,unassigned 3,2,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21990351&form=6&db=m Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22073239&form=6&db=m Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22385114&form=6&db=m Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22608962&form=6&db=m Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. therapeutic application,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22683241&form=6&db=m Synthesis and biological evaluation of isoxazole, oxazole, and oxadiazole containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors. causal interaction,therapeutic application,unassigned 2,1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22705711&form=6&db=m Acyl-CoA:diacylglycerol acyltransferase: Molecular biology, biochemistry and biotechnology. unassigned - 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22950654&form=6&db=m Proof of mechanism for the DGAT1 inhibitor AZD7687: Results from a first-time-in-human single dose study. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23336002&form=6&db=m Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23449193&form=6&db=m Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats. ongoing research,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23539897&form=6&db=m RNA interference-mediated knockdown of DGAT1 decreases triglyceride content of bovine mammary epithelial cell line. causal interaction,ongoing research,unassigned 4,2,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23871442&form=6&db=m Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24118885&form=6&db=m Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24735646&form=6&db=m Synthesis and evaluation of cyclohexane carboxylic acid head group containing isoxazole and thiazole analogs as DGAT1 inhibitors. therapeutic application,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24900321&form=6&db=m Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24900581&form=6&db=m Fighting Obesity and Metabolic Disorders with DGAT-1 Inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24900877&form=6&db=m Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24954424&form=6&db=m Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25112279&form=6&db=m Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25405858&form=6&db=m Intestine-targeted DGAT1 inhibition improves obesity and insulin resistance without skin aberrations in mice. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25640767&form=6&db=m Adipose tissue fatty acid storage factors: effects of depot, sex and fat cell size. unassigned - 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25738782&form=6&db=m Sex and Depot Differences in ex vivo Adipose Tissue Fatty Acid Storage and Glycerol-3-phosphate acyltransferase Activity. therapeutic application,unassigned 1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25857225&form=6&db=m JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26218650&form=6&db=m Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes. therapeutic application,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26354408&form=6&db=m JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26493024&form=6&db=m Prolonged silencing of diacylglycerol acyltransferase-1 induces a dedifferentiated phenotype in human liver cells. causal interaction,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26883093&form=6&db=m Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28243972&form=6&db=m Genetic interaction of DGAT2 and FAAH in the development of human obesity. causal interaction,ongoing research,unassigned 3,2,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29699923&form=6&db=m Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29706567&form=6&db=m DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates. causal interaction,therapeutic application,unassigned 2,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30251338&form=6&db=m Elevated metabolic rate and skeletal muscle oxidative metabolism contribute to the reduced susceptibility of NF-?B p50 null mice to obesity. causal interaction,unassigned 4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30641770&form=6&db=m Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity. causal interaction,ongoing research,unassigned 3,4,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31331203&form=6&db=m In silico design of diacylglycerol acyltransferase-1 (DGAT1) inhibitors based on SMILES descriptors using Monte-Carlo method. unassigned - 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32506038&form=6&db=m Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33347980&form=6&db=m A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism. causal interaction,therapeutic application,unassigned 4,3,0 2.3.1.20 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34160713&form=6&db=m Discovery of novel DGAT1 inhibitors by combination of machine learning methods, pharmacophore model and 3D-QSAR model. causal interaction,therapeutic application,unassigned 1,4,0 2.3.1.20 Obesity, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24529140&form=6&db=m Adipose tissue diacylglycerol acyltransferase activity and blood lipoprotein triglyceride enrichment in women with abdominal obesity. causal interaction,unassigned 3,0 2.3.1.20 Obesity, Morbid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23512750&form=6&db=m Reduced skeletal muscle oxidative capacity and elevatedceramidebut not diacylglycerol content in severe obesity. causal interaction,diagnostic usage,unassigned 3,2,0 2.3.1.20 Osteopetrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 Osteopetrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30401973&form=6&db=m Diversity of copy number variation in the worldwide goat population. unassigned - 2.3.1.20 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34095320&form=6&db=m DGAT1 Expression Promotes Ovarian Cancer Progression and Is Associated with Poor Prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 2.3.1.20 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24118885&form=6&db=m Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.20 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25854859&form=6&db=m Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.20 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26246845&form=6&db=m Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 2.3.1.20 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30641770&form=6&db=m Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity. causal interaction,ongoing research,unassigned 3,4,0 2.3.1.20 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34078402&form=6&db=m Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis. unassigned - 2.3.1.20 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27113481&form=6&db=m Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene. causal interaction,therapeutic application,unassigned 2,1,0 2.3.1.20 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28877685&form=6&db=m Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 2.3.1.20 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30816200&form=6&db=m DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 2.3.1.20 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33824421&form=6&db=m Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 2.3.1.20 Protein-Losing Enteropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26883093&form=6&db=m Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Protein-Losing Enteropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28937539&form=6&db=m Congenital Diarrhea from DGAT1 Mutation Leading to Electrolyte Derangements, Protein-Losing Enteropathy, and Rickets. unassigned - 2.3.1.20 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32546086&form=6&db=m Eicosapentaenoic acid attenuates renal lipotoxicity by restoring autophagic flux. ongoing research,unassigned 1,0 2.3.1.20 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32916011&form=6&db=m Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.20 Rickets http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28937539&form=6&db=m Congenital Diarrhea from DGAT1 Mutation Leading to Electrolyte Derangements, Protein-Losing Enteropathy, and Rickets. unassigned - 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6280682&form=6&db=m The activities of lipoprotein lipase and of enzymes involved in triacylglycerol synthesis in rat adipose tissue. Effects of starvation, dietary modification and of corticotropin injection. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,3,0 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21812932&form=6&db=m Cloning and molecular characterization of a novel acyl-CoA: diacylglycerol acyltransferase 1-like gene (PtDGAT1) from the diatom Phaeodactylum tricornutum. ongoing research,unassigned 3,0 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22403401&form=6&db=m Three acyltransferases and a nitrogen responsive regulator are implicated in nitrogen starvation-induced triacylglycerol accumulation in Chlamydomonas. unassigned - 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28222675&form=6&db=m Identification and characterization of an efficient acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) gene from the microalga Chlorella ellipsoidea. causal interaction,unassigned 3,0 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28454654&form=6&db=m The diacylglycerol acyltransferase Rv3371 of Mycobacterium tuberculosis is required for growth arrest and involved in stress-induced cell wall alterations. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28873005&form=6&db=m Recycling the Danger via Lipid Droplet Biogenesis After Autophagy. therapeutic application,unassigned 1,0 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29567958&form=6&db=m PHA-4/FoxA senses nucleolar stress to regulate lipid accumulation in Caenorhabditis elegans. unassigned - 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30218258&form=6&db=m Changes in the photosynthetic apparatus and lipid droplet formation in Chlamydomonas reinhardtii under iron deficiency. causal interaction,unassigned 2,0 2.3.1.20 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31850043&form=6&db=m Effect of Single and Combined Expression of Lysophosphatidic Acid Acyltransferase, Glycerol-3-Phosphate Acyltransferase, and Diacylglycerol Acyltransferase on Lipid Accumulation and Composition in Neochloris oleoabundans. ongoing research,unassigned 2,0 2.3.1.20 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32506038&form=6&db=m Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 2.3.1.20 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33750350&form=6&db=m Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 2.3.1.20 Syndactyly http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28018909&form=6&db=m A Review of Selected Genes with Known Effects on Performance and Health of Cattle. causal interaction,unassigned 3,0 2.3.1.20 Toxoplasmosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30061287&form=6&db=m Novel Approaches To Kill Toxoplasma gondii by Exploiting the Uncontrolled Uptake of Unsaturated Fatty Acids and Vulnerability to Lipid Storage Inhibition of the Parasite. therapeutic application,unassigned 4,0 2.3.1.20 triacylglycerol lipase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11805129&form=6&db=m Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands. causal interaction,ongoing research,unassigned 2,2,0 2.3.1.20 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16946266&form=6&db=m Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress. ongoing research,unassigned 3,0 2.3.1.20 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21602344&form=6&db=m Comparative genomics of the dormancy regulons in mycobacteria. unassigned - 2.3.1.20 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21819455&form=6&db=m The Mycobacterium tuberculosis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.20 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28454654&form=6&db=m The diacylglycerol acyltransferase Rv3371 of Mycobacterium tuberculosis is required for growth arrest and involved in stress-induced cell wall alterations. ongoing research,therapeutic application,unassigned 2,1,0